SEC Company Response from SINOVAC BIOTECH LTD (SVA) (CIK 0001084201) (SVA) — Sep 1, 2005
SINOVAC BIOTECH LTD (SVA) (CIK 0001084201)
Date: Sept. 1, 2005 · CIK: 0001084201 · Accession: 0001127855-05-000576
AI Filing Summary & Sentiment
Letter
SECURITIES AND EXCHANGE COMMISSION 450 5th Street N.W. Washington, D.C. U.S.A., 20549 – 0405 Attention: Mr. Mark Brunhofer, Staff Accountant, Division of Corporation Finance
Dear Mr. Brunhofer:
Re: Sinovac Biotech Ltd. (the “Company”)
Follow up acknowledgements on Form 20-F amendment
In connection with our filing of our amended Form 20-F/A-1 annual report via EDGAR on August 31, 2005, we acknowledge that:
the Company is responsible for the adequacy and accuracy of the disclosure in the filing;
staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Yours very truly,
Sinovac Biotech Ltd.
Per: /s/ Weidong Yin
Weidong Yin, President & CEO
Show Raw Text
CORRESP 1 filename1.htm Untitled Page SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District, Beijing P.R. China 100085 Tel: 86-10-82890088 Fax: 86-10-62966910 August 31, 2005 SECURITIES AND EXCHANGE COMMISSION 450 5th Street N.W. Washington, D.C. U.S.A., 20549 – 0405 Attention: Mr. Mark Brunhofer, Staff Accountant, Division of Corporation Finance Dear Mr. Brunhofer: Re: Sinovac Biotech Ltd. (the “Company”) Follow up acknowledgements on Form 20-F amendment In connection with our filing of our amended Form 20-F/A-1 annual report via EDGAR on August 31, 2005, we acknowledge that: the Company is responsible for the adequacy and accuracy of the disclosure in the filing; staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Yours very truly, Sinovac Biotech Ltd. Per: /s/ Weidong Yin Weidong Yin, President & CEO